List of Tables

Table 3.1	Calibration data for Gemcitabine Hydrochloride in distilled water.	69
Table 3.2	Parameters for estimation of Gemcitabine Hydrochloride in distilled water by UV Spectrophotometry.	71
Table 3.3	Calibration data for Gemcitabine Hydrochloride in PBS pH 7.4.	71
Table 3.4	Parameters for estimation of Gemcitabine Hydrochloride in PBS pH 7.4 by UV-Visible Spectrophotometry.	73
Table 3.5	Accuracy results for estimation of Gemcitabine Hydrochloride in distilled water.	73
Table 3.6	Accuracy results for estimation of Gemcitabine Hydrochloride in PBS pH 7.4.	73
Table 3.7	Precision results for estimation of Gemcitabine Hydrochloride in distilled water.	74
Table 3.8	Precision results for estimation of Gemcitabine Hydrochloride in PBS pH 7.4.	74
Table 3.9	Results of Analytical Interference Studies for Gemcitabine Hydrochloride.	75
Table 3.10	Calibration data for Gemcitabine Hydrochloride in rat plasma by LCMS-MS.	75
Table 3.11	Accuracy results for estimation of Gemcitabine Hydrochloride in rat plasma by LCMS-MS.	77
Table 3.12	Calibration data for Gemcitabine Hydrochloride extracted from rat heart homogenate by LCMS-MS.	78
Table 3.13	Accuracy results for estimation of Gemcitabine Hydrochloride from rat heart homogenate by LCMS-MS method.	79
Table 3.14	Calibration data for Gemcitabine Hydrochloride extracted from rat lungs homogenate by LCMS-MS.	79
Table 3.15	Accuracy results for estimation of Gemcitabine Hydrochloride from rat lungs homogenate by LCMS-MS method.	80
Table 3.16	Calibration data for Gemcitabine Hydrochloride extracted from rat liver homogenate by LCMS-MS.	81

Table 3.17	Accuracy results for estimation of Gemcitabine Hydrochloride from rat liver homogenate by LCMS-MS method.	82
Table 3.18	Calibration data for Gemcitabine Hydrochloride extracted from rat kidney homogenate by LCMS-MS.	82
Table 3.19	Accuracy results for estimation of Gemcitabine Hydrochloride from rat kidney homogenate by LCMS-MS method.	83
Table 3.20	Calibration data for Gemcitabine Hydrochloride extracted from rat spleen homogenate by LCMS-MS.	84
Table 3.21	Accuracy results for estimation of Gemcitabine Hydrochloride from rat spleen homogenate by LCMS-MS method.	85
Table 3.22	Calibration data for Vinorelbine Tartrate in distilled water.	85
Table 3.23	Parameters for estimation of Vinorelbine Tartrate in distilled water by UV-Visible spectrophotometry.	87
Table 3.24	Calibration data for Vinorelbine Tartrate in PBS pH 7.4.	87
Table 3.25	Parameters for estimation of Vinorelbine Tartrate in PBS pH 7.4 by UV-Visible spectrophotometry.	89
Table 3.26	Accuracy results for estimation of Vinorelbine Tartrate in distilled water.	89
Table 3.27	Accuracy results for estimation of Vinorelbine Tartrate in PBS pH 7.4.	89
Table 3.28	Precision results for estimation of Vinorelbine Tartrate in distilled water.	90
Table 3.29	Precision results for estimation of Vinorelbine Tartrate in PBS pH 7.4.	90
Table 3.30	Results of Analytical Interference Studies for Vinorelbine Tartrate.	91
Table 3.31	Calibration data for Vinorelbine tartrate in rat plasma by LCMS-MS.	91
Table 3.32	Accuracy results for estimation of Vinorelbine tartrate in rat plasma by LCMS-MS.	93
Table 3.33	Calibration data for Vinorelbine tartrate extracted from rat heart homogenate by LCMS-MS.	94

Table 3.34	Accuracy results for estimation of Vinorelbine tartrate from rat heart homogenate by LCMS-MS method.	95
Table 3.35	Calibration data for Vinorelbine tartrate extracted from rat lungs homogenate by LCMS-MS.	95
Table 3.36	Accuracy results for estimation of Vinorelbine tartrate from rat lungs homogenate by LCMS-MS method.	96
Table 3.37	Calibration data for Vinorelbine tartrate extracted from rat liver homogenate by LCMS-MS.	97
Table 3.38	Accuracy results for estimation of Vinorelbine tartrate from rat liver homogenate by LCMS-MS method.	98
Table 3.39	Calibration data for Vinorelbine tartrate extracted from rat kidney homogenate by LCMS-MS.	98
Table 3.40	Accuracy results for estimation of Vinorelbine tartrate from rat kidney homogenate by LCMS-MS method.	99
Table 3.41	Calibration data for Vinorelbine tartrate extracted from rat spleen homogenate by LCMS-MS.	100
Table 3.42	Accuracy results for estimation of Vinorelbine tartrate from rat spleen homogenate by LCMS-MS method.	101
Table 4.1	Principle functional groups and their characteristic peaks in GCH FTIR spectra.	106
Table 4.2	Principle functional groups and their characteristic peaks in physical mixture of GCH and excipients FTIR spectra.	108
Table 4.3	Principle functional groups and their characteristic peaks in VLB FTIR spectra.	110
Table 4.4	Principle functional groups and their characteristic peaks in physical mixture of VLB and excipients FTIR spectra.	112
Table 4.5	Screening of lipids (Lipid:Cholesterol ratio kept constant as 1:0.5 M).	113
Table 4.6	Different levels of cholesterol concentration in spherulites (SPC kept constant 1 M).	115
Table 4.7	Different levels of SPC:DSPE-PEG 2000 concentration in spherulites for PEGylation.	115
Table 4.8	Effect of hydration time on %EE and size of spherulites.	116

Table 4.9	Effect of Homogenization assembly.	117
Table 4.10	Effect of Homogenization time and speed on %EE spherulites.	119
Table 4.11	Effect of Homogenization time and speed on size (nm) of spherulites.	119
Table 4.12	Effect of number of extrusion cycles on %EE and size of Spherulites.	120
Table 5.1	Independent variables and their levels studied in 3^3 Full Factorial design.	125
Table 5.2	3^3 Full Factorial design batches with their measured responses (N=3; Mean±SD).	127-128
Table 5.3	Results of Checkpoint analysis of GCH loaded spherulites.	135
Table 5.4	Composition of GCH loaded Non-PEGylated and PEGylated spherulites.	135
Table 5.5	Independent variables and their levels studied in Box-Behnken design.	136
Table 5.6	Box-Behnken design batches with their measured responses (N=3; Mean±SD).	138
Table 5.7	Results of Checkpoint analysis of VLB loaded spherulites.	145
Table 5.8	Composition of VLB loaded Non-PEGylated and PEGylated spherulites.	145
Table 6.1	Results of size and zeta potential for GCH loaded Non-PEGylated and GCH loaded PEGylated Spherulites. Data represents mean of three experimental values (n=3; mean±SD).	152
Table 6.2	Results of % EE and % drug loading (% w/w) for GCH loaded Non-PEGylated and GCH loaded PEGylated Spherulites. Data represents mean of three experimental values (n=3; mean±SD).	154
Table 6.3	*In Vitro* drug release study of Standard GCH solution, GCH loaded Non-PEGylated Spherulites and GCH loaded PEGylated Spherulites. Data represents mean of three experimental values (n=3; mean±SD).	158

Table 6.4	Results of osmolality determination of GCH loaded Non-PEGylated Spherulites and GCH loaded PEGylated Spherulites. Data represents mean of three experimental values (n=3; mean±SD).	159
Table 6.5	Results of Electrolyte-induced flocculation study of GCH loaded Non-PEGylated Spherulites and GCH loaded PEGylated Spherulites. Data represents mean of three experimental values (n=3; mean±SD).	160
Table 6.6	Results of size and zeta potential for VLB loaded Non-PEGylated and VLB loaded PEGylated Spherulites. Data represents mean of three experimental values (n=3; mean±SD).	161
Table 6.7	Results of % EE and % drug loading (% w/w) for VLB loaded Non-PEGylated and VLB loaded PEGylated Spherulites. Data represents mean of three experimental values (n=3; mean±SD).	164
Table 6.8	*In Vitro* drug release study of Standard VLB solution, VLB loaded Non-PEGylated Spherulites and VLB loaded PEGylated Spherulites. Data represents mean of three experimental values (n=3; mean±SD).	167
Table 6.9	Results of osmolality determination of VLB loaded Non-PEGylated Spherulites and VLB loaded PEGylated Spherulites. Data represents mean of three experimental values (n=3; mean±SD).	168
Table 6.10	Results of Electrolyte-induced flocculation study of VLB loaded Non-PEGylated Spherulites and VLB loaded PEGylated Spherulites. Data represents mean of three experimental values (n=3; mean±SD).	169
Table 7.1	% Cell Inhibition values with respect to time of standard GCH drug and GCH loaded spherulites on A549 cell line.	178
Table 7.2	IC50 values of standard GCH drug and GCH loaded spherulites in A549 cell line.	178

Table 7.3	% Cell Inhibition values with respect to time of standard VLB drug and VLB loaded spherulites on A549 cell line.	181
Table 7.4	IC50 values of standard VLB drug and VLB loaded spherulites in A549 cell line.	182
Table 7.5	Cell Cycle Analysis of A549 cell line after treatment with untreated cells as control, Standard GCH (Std GCH) and GCH loaded spherulites, by PI staining using FACS technique.	184
Table 7.6	Cell Cycle Analysis of A549 cell line after treatment with Untreated cells as control, Standard VLB (Std VLB) and VLB loaded spherulites, by PI staining using FACS technique.	187
Table 8.1	*In vivo* pharmacokinetic parameters of Standard GCH solution, GCH loaded non-PEGylated Spherulites and GCH loaded PEGylated Spherulites administered intravenously via tail vein in Female SD rats (n=6) (Data represents mean±SD).	203
Table 8.2	*In vivo* pharmacokinetic parameters of Standard VLB solution, VLB loaded non-PEGylated Spherulites and VLB loaded PEGylated Spherulites administered intravenously via tail vein in Female SD rats (n=6) (Data represents mean±SD).	205
Table 8.3	Biodistribution of Standard GCH solution in rats in highly perfused organs as function of time (n=3) (Data represents mean±SD).	207
Table 8.4	Biodistribution of GCH loaded non-PEGylated Spherulites in rats in highly perfused organs as function of time (n=3) (Data represents mean±SD).	208
Table 8.5	Biodistribution of GCH loaded PEGylated Spherulites in rats in highly perfused organs as function of time (n=3) (Data represents mean±SD).	209
Table 8.6	Biodistribution of Standard VLB solution in rats in highly perfused organs as function of time (n=3) (Data represents mean±SD).	211
Table 8.7	Biodistribution of VLB loaded non-PEGylated Spherulites in rats in highly perfused organs as function of time (n=3) (Data represents mean±SD).	212

Table 8.8	Biodistribution of VLB loaded PEGylated Spherulites in rats in highly perfused organs as function of time (n=3) (Data represents mean±SD).	213
Table 8.9	^{99m}Tc-GCH complex stability in serum and saline (n=3; mean±SD).	216
Table 8.10	^{99m}Tc-VLB complex stability in serum and saline (n=3; mean±SD).	223
Table 9.1	Stability study of GCH loaded Non-PEGylated spherulites at Refrigerated condition (2-8°C). Data represents mean of three experimental values (n=3; mean±SD).	234
Table 9.2	Stability study of GCH loaded Non-PEGylated spherulites at 25°C±2°C, 60±5 RH (room temperature). Data represents mean of three experimental values (n=3; mean±SD).	234
Table 9.3	Stability study of GCH loaded PEGylated spherulites at Refrigerated condition (2-8°C). Data represents mean of three experimental values (n=3; mean±SD).	235
Table 9.4	Stability study of GCH loaded PEGylated spherulites at 25°C±2°C, 60±5 RH (room temperature). Data represents mean of three experimental values (n=3; mean±SD).	236
Table 9.5	Stability study of VLB loaded Non-PEGylated spherulites at Refrigerated condition (2-8°C). Data represents mean of three experimental values (n=3; mean±SD).	237
Table 9.6	Stability study of VLB loaded Non-PEGylated spherulites at 25°C±2°C, 60±5 RH (room temperature). Data represents mean of three experimental values (n=3; mean±SD).	238
Table 9.7	Stability study of VLB loaded PEGylated spherulites at Refrigerated condition (2-8°C). Data represents mean of three experimental values (n=3; mean±SD).	239
Table 9.8	Stability study of VLB loaded PEGylated spherulites at 25°C±2°C, 60±5 RH (room temperature). Data represents mean of three experimental values (n=3; mean±SD).	239